CLINICAL NEWS
On Location ASH 2016 Inside Look
Session Sneak Peek
Scientific Committee on Blood
Disorders in Childhood and Scientific
Committee on Red Cell Biology:
Understanding and Repairing Faulty
Red Blood Cells
SATURDAY, DECEMBER 3, 2016, 9:30 – 11:30 A.M. and
SUNDAY, DECEMBER 4, 2016, 9:30 – 11:30 A.M.
co-chairs
Colleen Delaney, MD, Fred Hutchinson Cancer Research Center, Seattle, WA
Alex Minella, MD, BloodCenter of Wisconsin, Milwaukee, WI
and lineage fate decisions at the single-cell level.
Dr. Dick will describe clonal evolution of human hematopoiesis at
single-cell resolution; Dr. Gottgens will present single-cell molecular profiling
experiments that reveal new aspects of blood stem cell regulation and their
perturbation by leukemic factors; Dr. Rothenberg will present a systems biology level understanding of the transcription networks that control lymphoid
cell fate decisions; Dr. Schroeder will present his work using transcription
factor reporters to track myeloid lineage fate determination.
Grassroots Network Lunch
SATURDAY, DECEMBER 3, 2016, 11:00 A.M. – 12:15 P.M.
speakers
speaker
Ann Dean, PhD, National Institute of Diabetes and Digestive and Kidney
Diseases, National Institutes of Health, Bethesda, MD
Harvey Lodish, PhD, Whitehead Institute for Biomedical Research, Cambridge, MA
Lucia De Franceschi, MD, Policlinico GB Rossi, University of Verona, Verona, Italy
Marina Cavazzana, MD, PhD, Hôpital Necker – Enfants, Paris, France
Gregory C. Simon, Office of the Vice President
Fundamental insights into the relationships between gene structure and
transcriptional control, gained using erythroid cell systems, have driven the
development of novel therapeutic approaches to red blood cell diseases,
including sickle cell anemia and thalassemias. The development of these
approaches represents a paradigm for future molecularly targeted therapies.
This session will combine presentations of newly elucidated, fundamental
mechanisms of cell signaling and gene expression control, with demonstrations of ongoing, state-of-the-art studies of gene therapy strategies aimed
at treating and curing hemoglobinopathies in humans.
Dr. Dean will focus on the biology of gene regulatory elements that regulate
transcription through long-range interactions with promoter regions; Dr. Lodish
will present ongoing work focused on harnessing an integrative, mechanistic
understanding of erythroid progenitor cell signaling pathways; Dr. De Franceschi
will describe the development of non-gene therapy strategies for clinical application; and Dr. Cavazzana will present novel therapeutic approaches in an effort
to cure the more prevalent inherited blood diseases worldwide.
Thanks to ASH’s advocacy efforts and the ASH Grassroots Network, issues
important to the future of hematology are brought to the attention of the U.S.
Congress and federal agencies. The ASH Grassroots Network Lunch provides a
forum for interested members to learn how they can participate in ASH’s advocacy efforts, communicate with Congress and the White House, and become
effective advocates for hematology. Greg Simon, executive director of the White
House Cancer Task Force and the Obama Administration’s Cancer Moonshot
initiative, will be the featured speaker at this year’s lunch. Mr. Simon will discuss
the achievements of Moonshot thus far, including the findings of the initiative’s
Blue Ribbon Panel, the recently released Cancer Moonshot Taskforce Report,
and the outlook for the effort in the next presidential administration.
Special Scientific Symposium on
Genomic Instability in Lymphoid
Development: Causes and
Consequences
SATURDAY, DECEMBER 3, 2016, 4:00 – 5:30 P.M.
speakers
Brian Druker, MD, Oregon Health & Science University, Portland, OR
Keith Flaherty, MD, Massachusetts General Hospital, Boston, MA
This Scientific Spotlight Session will discuss the state of precision medicine
clinical trials that incorporate genomic profiling to understand the molecular
basis of therapeutic response. Dr. Druker will speak about progress in precision medicine approaches to treat acute myeloid leukemia (AML) and provide
updates on an umbrella trial design to identify rational therapies for AML
based on recurrent molecular abnormalities in these leukemias. Dr. Flaherty
will discuss the NCI-MATCH basket trial, which is enrolling patients with a
wide range of cancer types and assigning them to treatment arms based on
deep amplicon resequencing of known cancer genes.
ASH–College of American
Pathologists Guidelines on Initial
Work-Up of Acute Leukemia
SUNDAY, DECEMBER 4, 2016, 4:30 – 6:00 P.M.
speakers
Daniel A. Arber, MD, Stanford University Medical Center, Stanford, CA
Kathryn Foucar, MD, University of New Mexico Health Sciences Center,
Albuquerque, NM
The laboratory evaluation of patients suspected of having acute leukemia is
complex. The College of American Pathologists (CAP) and ASH formed an expert
panel to review the relevant literature and to establish a guideline for appropriate laboratory testing (e.g., guidance on which genetic tests should be ordered
for diagnosis) as well as clinical information for the initial diagnosis of acute
leukemia, including acute myeloid leukemia, acute lymphocytic leukemia, and
acute leukemias of ambiguous lineage. In this session, Drs. Arber and Foucar
will describe the process used for the development of the acute leukemia
guidelines and summarize the guideline statements, the strength of evidence
for each statement, and the rationale for the specific elements.
chair
Scientific Committee on Hematopoiesis and Scientific Committee
on Myeloid Biology: Clonal Development of Hematopoietic Stem Cell
Specification and Differentiation at
Single Cell Resolution
SATURDAY, DECEMBER 3, 2016, 9:30 – 11:30 A.M. and
SUNDAY, DECEMBER 4, 2016, 9:30 – 11:30 A.M.
co-chairs
Yi Zheng, PhD, Cincinnati Children’s Hospital, Cincinnati, OH
H. Leighton Grimes, PhD, Cincinnati Children’s Hospital, Cincinnati, OH
speakers
John Dick, PhD, The Princess Margaret Cancer Centre, Toronto, Canada
Bertie Gottgens, DPhil, University of Cambridge, Cambridge, United Kingdom
Ellen Rothenberg, PhD, California Institute of Technology, Pasadena, CA
This session will focus on cutting-edge, integrated single-cell genomic and
genetic analysis of hematopoiesis, coupled with single-cell biology. Together,
these approaches provide new knowledge of the molecular networks that
resolve hematopoietic cellular processes in both human and model systems,
expanding our understanding of how clonality is achieved and dynamically
controlled in both normal and disease states of blood cell development. This
work will expand our understanding of clonal selection/clonal dominance,
76
ASH Clinical News
Richard Ambinder, MD, PhD, The Johns Hopkins University School of Medicine, Baltimore, MD
speakers
Stephen Desiderio, MD, PhD, The Johns Hopkins University School of
Medicine, Baltimore, MD
Barry Sleckman, MD, PhD, Weill Cornell Medical College, New York, NY
Markus Müschen, MD, PhD, University of California – San Francisco, San
Francisco, CA
The ASH Choosing Wisely®
Campaign: 2016 ASH Choosing
Wisely Champions
MONDAY, DECEMBER 5, 2016, 12:15 – 1:15 P.M.
chair
Lisa K. Hicks, MD, St. Michael’s Hospital, Toronto, Canada
As part of the new joint committee sessions in this year’s program, this
presentation will describe new insights into the role of genomic instability
in normal lymphoid development and in neoplasia. Recent investigations in
mouse models and in clinical specimens shed new light on the regulation of
recombination mediated by the RAG proteins, double strand breaks, the DNA
damage response and cell-cycle checkpoints. Dr. Desiderio will discuss genomic
instability in developing lymphocytes; Dr. Sleckman will discuss the coordination
of recombination and DNA repair in developing lymphocytes; and Dr. Müschen
will discuss the clonal evolution of acute lymphoblastic malignancies.
speakers
Precision Medicine Trials as a Novel
Approach to Drug Development
In cooperation with the American Board of Internal Medicine Foundation, ASH is introducing the “Choosing Wisely Champions” to recognize
the efforts of practitioners who are working to eliminate costly and the
potentially harmf ul overuse of tests and procedures and to provide annual
meeting attendees with an opportunity to learn about projects that might
be translated to their own practices. These three individuals will present
successful strategies that they have developed and implemented in their
practice, institution, or hospital system.
SUNDAY, DECEMBER 4, 2016, 4:30 – 6:00 P.M.
chair
Louis Staudt, MD, PhD, National Cancer Institute, National Institutes of
Health, Bethesda, MD
Maria I. Juarez, MD, Cancer Institute of Dallas, Mansfield, TX
Reduction of RBC Transfusion Via Updated Guidelines, Modified Workflow, and
Physician Education
Javier Munoz, MD, Banner MD Anderson Cancer Center, Gilbert, AZ
Reduction of Post-Treatment Scanning Using EMR Alerts
Ravindra Sarode, MD, University of Texas Southwestern Medical Center,
Dallas, TX
Reduction in Unnecessary or Misapplied Thrombophilia Testing in Patients with DVT,
PE, or Other Thrombotic Disorders Using Combination of Education and EMR Alerts
December 2016